Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2024

Revenue Recognition

Schedule of disaggregation of revenue

	Three Months Ended June 30,				Six Months Ended June 30,
	2024		2023			2024	2023
Collaborative revenue
CSL Vifor (KORSUVA injection profit sharing)	$	—	$	5,410	$	788	$	8,160
Total collaborative revenue	$	—	$	5,410	$	788	$	8,160
Commercial supply revenue
CSL Vifor (KORSUVA injection)	$	—	$	1,400	$	640	$	4,591
Total commercial supply revenue	$	—	$	1,400	$	640	$	4,591
Royalty revenue
CSL Vifor (Kapruvia ex-U.S.)	$	—	$	123	$	—	$	248
Total royalty revenue	$	—	$	123	$	—	$	248
Clinical compound revenue
Maruishi	$	—	$	—	$	84	$	99
Total clinical compound revenue	$	—	$	—	$	84	$	99
Other revenue (non-cash)
CSL Vifor (Kapruvia ex-U.S.)	$	359	$	—	$	649	$	—
Maruishi		632		—		965		—
Total other revenue	$	991	$	—	$	1,614	$	—